Daan Gene 過去の業績

過去基準チェック /06

Daan Geneの収益は年間平均-3.4%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間5.9% 2%割合で増加しています。

主要情報

-3.4%

収益成長率

-3.4%

EPS成長率

Biotechs 業界の成長	11.3%
収益成長率	2.0%
株主資本利益率	-9.0%
ネット・マージン	-80.7%
前回の決算情報	30 Sep 2024

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 05

Recent updates

Health Check: How Prudently Does Daan Gene (SZSE:002030) Use Debt?

Oct 24

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

Aug 20

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

May 02

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 05

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Mar 25

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Mar 06

収支内訳

Daan Gene の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SZSE:002030 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	930	-751	586	247
30 Jun 24	1,045	-697	480	269
31 Mar 24	1,038	-295	468	282
31 Dec 23	1,181	105	442	302
30 Sep 23	3,553	854	896	494
30 Jun 23	5,906	2,221	1,060	585
31 Mar 23	9,025	3,769	1,148	659
01 Jan 23	12,046	5,412	1,543	702
30 Sep 22	11,363	6,004	1,182	669
30 Jun 22	10,858	5,615	1,281	594
31 Mar 22	8,687	4,170	1,345	568
01 Jan 22	7,664	3,618	1,255	509
30 Sep 21	7,419	3,436	1,383	329
30 Jun 21	6,691	3,268	1,167	273
31 Mar 21	7,092	3,391	1,350	200
31 Dec 20	5,341	2,449	1,034	167
30 Sep 20	3,890	1,549	989	148
30 Jun 20	2,715	810	914	135
31 Mar 20	1,435	250	559	105
31 Dec 19	1,098	92	524	95
30 Sep 19	1,060	103	341	88
30 Jun 19	1,190	103	344	96
31 Mar 19	1,343	102	386	95
31 Dec 18	1,479	102	425	99
30 Sep 18	1,575	89	465	86
30 Jun 18	1,575	88	426	132
31 Mar 18	1,581	88	449	114
31 Dec 17	1,542	87	478	92
30 Sep 17	1,609	98	510	73
30 Jun 17	1,594	101	570	0
31 Mar 17	1,627	107	582	0
31 Dec 16	1,613	107	565	0
30 Sep 16	1,638	107	503	0
30 Jun 16	1,636	105	495	0
31 Mar 16	1,536	102	462	0
31 Dec 15	1,474	101	439	0
30 Sep 15	1,322	133	398	0
30 Jun 15	1,223	153	363	0
31 Mar 15	1,150	153	349	0
31 Dec 14	1,086	153	338	0
30 Sep 14	1,016	123	330	0
30 Jun 14	964	147	344	0
31 Mar 14	903	145	319	0
31 Dec 13	854	144	317	0

質の高い収益: 002030は現在利益が出ていません。

利益率の向上: 002030は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 002030は利益が出ておらず、過去 5 年間で損失は年間3.4%の割合で増加しています。

成長の加速: 002030の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 002030は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 0.08% ) と比較することは困難です。

株主資本利益率

高いROE: 002030は現在利益が出ていないため、自己資本利益率 ( -9.02% ) はマイナスです。

Daan Gene 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.035 loss in 3Q 2023)

Daan Gene Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.27 profit in 2Q 2023)

Daan Gene Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

First quarter 2024 earnings released: CN¥0.26 loss per share (vs CN¥0.026 profit in 1Q 2023)

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Recent updates

Third quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.035 loss in 3Q 2023)

Health Check: How Prudently Does Daan Gene (SZSE:002030) Use Debt?

Daan Gene Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.27 profit in 2Q 2023)

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

Daan Gene Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Dividend reduced to CN¥0.015

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 14 June 2024

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

First quarter 2024 earnings released: CN¥0.26 loss per share (vs CN¥0.026 profit in 1Q 2023)

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.075 (vs CN¥3.86 in FY 2022)

Daan Gene Co., Ltd., Annual General Meeting, Apr 19, 2024

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

Now 20% overvalued

Daan Gene Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: CN¥0.035 loss per share (vs CN¥0.94 profit in 3Q 2022)

Daan Gene Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥1.36 in 2Q 2022)

Less than half of directors are independent

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 13, 2023

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: CN¥3.95 (vs CN¥2.58 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.94 (vs CN¥0.66 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.36 (vs CN¥0.33 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.34 (vs CN¥0.33 in 2Q 2021)

Insufficient new directors

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥1.11 per share

Daan Gene Co., Ltd. Proposes Final Cash Dividend on A Shares for the Year 2021, Payable on May 9, 2022

Insufficient new directors

Daan Gene Co., Ltd. Approves Final Dividend for the Year 2021

Daan Gene Co., Ltd., Annual General Meeting, Apr 20, 2022

Daan Gene Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.66 (vs CN¥0.54 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Da An Gene Co., Ltd. of Sun Yat-Sen University Announces Final Dividend Implementation Plan (A Shares) for 2020, Payable on 19 May 2021

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.21 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.77 (vs CN¥0.10 in FY 2019)

New 90-day low: CN¥29.03

Da an Gene Co., Ltd. of Sun Yat-Sen University Announces Executive Changes

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report Fiscal Year 2020 Results on Mar 31, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.15

New 90-day low: CN¥31.98

Third quarter 2020 earnings released: EPS CN¥0.86

First half earnings released

First half earnings released

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥40.83

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06